Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00815854 · ClinicalTrials.gov registry record · NA

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

A NA study of Schizophrenia, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
88
Enrollment target
1
Study location

NCT00815854: Completed NA study of Schizophrenia, sponsored by University of Michigan.

NCT00815854 is a NA study of Schizophrenia that has completed, run by University of Michigan. The registered enrollment target is 88 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00815854, a NA study of Schizophrenia, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
88 participants
Enrollment target
1
Study location

Study Summary

This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.

Primary Outcome

Using the EndoPAT machine (Itamar) we will measure the Reactive hyperemia index (RHI)

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Folic Acid

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2008-10
Est. Completion 2019-05
Phase NA
University of Michigan

1,327 total trials

What the finished NCT00815854 record still lists

NCT00815854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00815854 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT00815854 about?

NCT00815854 is a clinical study titled "Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects". This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.

What is the current status of trial NCT00815854?

This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2008-10. Estimated completion is 2019-05.

What conditions does trial NCT00815854 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00815854?

The interventions under investigation include: Placebo (OTHER), Folic Acid (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00815854?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00815854 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00815854's enrollment target sits among peer trials

88 153rd of 315 higher than 162 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00815854, the US trial registry maintained by the National Library of Medicine. NCT00815854 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.